Entered into a clinical collaboration to evaluate the combination of Zymeworks’ zanidatamab, a HER2-targeted bispecific antibody, and ALX148, a next-generation CD47 blocker, for the treatment of patients with advanced HER2-expressing breast cancer and other solid tumors. Zymeworks is the sponsor of the study.
Collaboration with BeiGene for the research, development, and commercialization of zanidatamab and ZW49 in Asia (excluding Japan), Australia, and New Zealand and also the research, development, and commercialization of up to three bispecific antibody therapeutics globally enabled using Zymeworks’ proprietary Azymetric™ and EFECT™ platforms.
Collaboration with Bristol-Myers Squibb (originally with Celgene) for the research, development, and commercialization of up to ten bispecific antibody therapeutics enabled using Zymeworks’ proprietary Azymetric™ and EFECT™ platforms.
Collaboration with Daiichi Sankyo for the research, development, and commercialization of up to three total bispecific antibody therapeutics enabled using Zymeworks’ proprietary Azymetric™ and EFECT™ platforms. Zymeworks also obtained rights to develop antibody therapeutics using certain Daiichi Sankyo’s immuno-oncology antibodies.
Collaboration with Eli Lilly for the research, development, and commercialization of a bispecific immuno-oncology therapeutic enabled using Zymeworks’ proprietary Azymetric™ platform.
Collaboration with GSK for the further development of Zymeworks’ EFECT™ platform through the design, engineering, and testing of novel engineered Fc domains tailored to induce specific antibody-mediated immune responses. Both GSK and Zymeworks will have the right to develop and commercialize therapeutic antibody candidates incorporating the optimized immune-modulating Fc domains.
Collaboration with GSK for the research, development, and commercialization of up to six bispecific antibody therapeutics, including for applications in infectious diseases, enabled using Zymeworks’ proprietary Azymetric™ platform.
Collaboration with Iconic for the research, development, and commercialization of XB002 (formerly ICON-2) tissue factor ADC for cancer, enabled using Zymeworks’ proprietary ZymeLink™ platform. XB002 has been sublicensed to Exelixis for all further clinical development and commercialization.
Collaboration with Johnson & Johnson (Janssen Biotech, Inc.) for the research, development, and commercialization of up to six bispecific antibody therapeutics enabled using Zymeworks' Azymetric™ and EFECT™ platforms.
Collaboration with LEO Pharma for the discovery, development, and commercialization of bispecific antibody therapeutics targeting cytokine-receptor pathways enabled using Zymeworks’ proprietary Azymetric™ and EFECT™ platforms. LEO Pharma to retain rights in dermatology indications while Zymeworks retains rights in all other therapeutic areas.
Entered into a clinical collaboration to evaluate the combination of Pfizer’s Ibrance® (palbociclib), an oral CDK4/6 inhibitor, and the hormone therapy fulvestrant with Zymeworks’ zanidatamab in patients with previously-treated locally advanced and/or metastatic HER2-positive, HR-positive breast cancer. Zymeworks is the sponsor of the study and Pfizer is providing palbociclib.
